Phase 2 N=23 Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Mixed Tumor, Mullerian
Primary: Number of Participants With Overall Response — 8 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Mixed Mullerian Tumors of the Uterus
Primary: Chemotherapy Completion Rate — 100 percentage of participants
Phase 2 N=30 Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
Uterine Cancer
Primary: Cycles With Hematologic Toxicities — 11; 14; 6; 0 Cycles
Phase 2 N=20 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Sarcoma
Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 participants
Phase 1 N=24 Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
Carcinosarcoma, Ovarian
Primary: Proportion of Patients With Completion of 4 Cycles of CT + GB — 0.7826 proportion of patients
Phase 2 N=25 Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Recurrent Endometrial Cancer
Primary: Frequency of Objective Tumor Response as Assessed by RECIST 1.1- Overall Response Rate (ORR) — 5; 9; 7; 3 Participants — p=0.024
Phase 2 N=81 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Uterine Cancer
Primary: To Evaluate the Toxicity and Tolerability of Pelvic Radiation "Sandwiched" Between Cycles of Paclitaxel/Carboplatin Chemotherapy in Patients With UPSC — 65.5; 25.8…
Phase 2 N=47 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Leiomyosarcoma · Uterine Neoplasm
Primary: Two-year Progression-free Survival Among Women Treated With This Adjuvant Regimen for High Risk Uterine LMS — 78 percentage of participants — p=0.15
Phase 2 N=20 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Therapy Completion Rate — .75 proportion of participants
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Phase 2 N=23 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants
N/A N=221 Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Endometrial Cancer
Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months
Phase 2 N=55 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
Recurrent Uterine Corpus Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 17.8 percentage of participants
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
Phase 3 N=301 PGL4001 Versus GnRH-agonist in Uterine Myomas
Uterine Myomas
Primary: Percentage of Subjects With Reduction of Uterine Bleeding at Week 13 Visit Defined as Pictorial Blood-loss Assessment Chart (PBAC) Score < 75 at End-of-treatment Visit…
Phase 2 N=30 A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer
Uterine Cancer
Primary: 3-year Overall Survival — 17 partipants
N/A N=11 Clinical Evaluation of the Interlace Medical Hysteroscopic Morcellator
Abnormal Uterine Bleeding · Infertility
Primary: Percentage of Tissue Removed — 97.5 Percentage of tissue removed
Phase 2 N=55 Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer
Sarcoma
Primary: Nature and Degree of Toxicity — 2; 4; 20; 19 Participants
Phase 2 N=24 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Cancer · Ovarian Cancer · Primary Peritoneal Cavity Cancer
Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=26 Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
Recurrent Uterine Sarcoma · Uterine Carcinosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 4.3 percentage of participants
Phase 4 N=12 Pilot of Letrozole for Uterine Myomas
Leiomyoma · Uterine Fibroids
Primary: Changes in Fibroid-related Symptoms After Treatment With Letrozole — -10.42; 1.43 units on a scale — p=0.24
Phase 2 N=20 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma
Metastatic Leiomyosarcoma · Unresectable Leiomyosarcoma · Uterine Corpus Leiomyosarcoma
Primary: Objective Response Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Among Patients With Advanced Leiomyosarcoma of the Uterus (ULMS) Treated With Nivolumab…
Phase 2 N=56 Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
Recurrent Uterine Sarcoma · Stage III Uterine Sarcoma · Stage IV Uterine Sarcoma
Primary: Objective Overall Response Rate — 2; 0 participants
Phase 2 N=26 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Leiomyosarcoma
Primary: Progression Free Survival Rate at 12 Weeks — 46 percentage of participants
Phase 2 N=33 Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
N/A N=33 Therapeutic Magnetic Resonance Imaging (MRI)-Guided High Intensity Focused Ultrasound (HIFU) Ablation of Uterine Fibroids
Uterine Fibroids
Primary: Adverse Events/Subject Resulting From HIFU Treatment of the Uterine Fibroids — 2.6 Adverse Event/subject
Phase 3 N=255 Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location
Persistent Pregnancy of Unknown Location · Ectopic Pregnancy
Primary: Number of Participants With Uneventful Clinical Resolution of a Pregnancy of Unknown Location Without Change From the Initial Management Strategy — 31; 42; 45 Participants